文献速递临床试验与 GCP医学人工智能与信息学

预测辅助减量生物制剂治疗类风湿关节炎患者(PATIO):一项随机对照试验方案

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2022-06-16

本研究为研究者发起的多中心、开放标签、1:1随机对照试验,拟纳入160例病情稳定低活动度且接受bDMARD治疗的RA患者,评估将 flare 风险预测模型纳入bDMARD减量策略对18个月内 flare 次数的影响,对照组按疾病活动度指导剂量优化(DGDO)减量,干预组在DGDO基础上结合动态 flare 预测模型、高风险时不进行下一步减量。

要点

  • 稳定低疾病活动度或缓解的RA患者应考虑bDMARD减量。
  • 减量过程虽不影响长期疾病控制,但短期 flare 频繁。
  • 在DGDO减量策略中结合动态 flare 预测模型可能降低减量期间 flare 风险。

核心结论

  • 这是首个评估在bDMARD减量期间应用动态 flare 预测模型作为决策辅助的临床试验。
  • 降低减量期间 flare 风险可能提高bDMARD治疗的安全性和成本效果。
  • 本研究开创了将预测算法应用于临床实践的领域。

研究设计与样本

  • 研究者发起的多中心、开放标签、1:1随机对照试验。
  • 拟招募160例接受bDMARD治疗且病情稳定低活动度的RA患者。
  • 对照组按疾病活动度指导剂量优化(DGDO)减量,干预组按DGDO联合动态 flare 预测模型的策略减量,高风险时不进行下一步减量。
  • 主要结局为18个月随访期间每例患者的 flare 次数(DAS28-CRP升高>1.2,或DAS28-CRP升高>0.6且当前DAS28-CRP≥2.9)。

主要发现

  • 尚未报告研究结果。

关键数值与推荐

  • 主要结局的 flare 定义:DAS28-CRP升高>1.2,或DAS28-CRP升高>0.6且当前DAS28-CRP≥2.9。
  • 次要结局包括重大 flare(持续时间≥12周)的患者数、bDMARD剂量减少、不良事件、疾病活动度(DAS28-CRP)及患者报告结局(生活质量和功能残疾)。
  • 还将评估医疗资源利用和工作生产力。

临床怎么用

  • 对于病情稳定低活动度或缓解的RA患者,应考虑bDMARD减量。
  • 减量过程中应关注短期 flare 风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biological disease-modifying anti-rheumatic drugs (bDMARDs) are effective in the treatment of rheumatoid arthritis (RA) but are expensive and increase the risk of infection. Therefore, in patients with a stable low level of disease activity or remission, tapering bDMARDs should be considered. Although tapering does not seem to affect long-term disease control, (short-lived) flares are frequent during the tapering process. We have previously developed and externally validated a dynamic flare prediction model for use as a decision aid during stepwise tapering of bDMARDs to reduce the risk of a flare during this process. METHODS: In this investigator-initiated, multicenter, open-label, randomized (1:1) controlled trial, we will assess the effect of incorporating flare risk predictions into a bDMARD tapering strategy. One hundred sixty RA patients treated with a bDMARD with stable low disease activity will be recruited. In the control group, the bDMARD will be tapered according to "disease activity guided dose optimization" (DGDO). In the intervention group, the bDMARD will be tapered according to a strategy that combines DGDO with the dynamic flare prediction model, where the next bDMARD tapering step is not taken in case of a high risk of flare. Patients will be randomized 1:1 to the control or intervention group. The primary outcome is the number of flares per patient (DAS28-CRP increase > 1.2, or DAS28-CRP increase > 0.6 with a current DAS28-CRP ≥ 2.9) during the 18-month follow-up period. Secondary outcomes include the number of patients with a major flare (flare duration ≥ 12 weeks), bDMARD dose reduction, adverse events, disease activity (DAS28-CRP) and patient-reported outcomes such as quality of life and functional disability. Health Care Utilization and Work Productivity will also be assessed. DISCUSSION: This will be the first clinical trial to evaluate the benefit of applying a dynamic flare prediction model as a decision aid during bDMARD tapering. Reducing the risk of flaring during tapering may enhance the safety and (cost)effectiveness of bDMARD treatment. Furthermore, this study pioneers the field of implementing predictive algorithms in clinical practice. TRIAL REGISTRATION: Dutch Trial Register number NL9798, registered 18 October 2021, https://www.trialregister.nl/trial/9798 . The study has received ethical review board approval (number NL74537.041.20).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Messelink MA, van der Leeuw MS, den Broeder AA, et al. Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial. Trials. 2022. PMID: 35710576. doi:10.1186/s13063-022-06471-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。